Compare Cipla with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs DR. REDDYS LAB - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA DR. REDDYS LAB CIPLA/
DR. REDDYS LAB
 
P/E (TTM) x 34.2 40.4 84.6% View Chart
P/BV x 4.8 5.5 87.4% View Chart
Dividend Yield % 0.4 0.5 88.1%  

Financials

 CIPLA   DR. REDDYS LAB
EQUITY SHARE DATA
    CIPLA
Mar-20
DR. REDDYS LAB
Mar-20
CIPLA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs5863,363 17.4%   
Low Rs3572,352 15.2%   
Sales per share (Unadj.) Rs207.01,054.2 19.6%  
Earnings per share (Unadj.) Rs18.6121.9 15.3%  
Cash flow per share (Unadj.) Rs33.2190.2 17.4%  
Dividends per share (Unadj.) Rs4.0025.00 16.0%  
Dividend yield (eoy) %0.80.9 97.0%  
Book value per share (Unadj.) Rs195.5938.7 20.8%  
Shares outstanding (eoy) m806.35166.17 485.3%   
Bonus/Rights/Conversions ESOSESOP-  
Price / Sales ratio x2.32.7 84.0%   
Avg P/E ratio x25.323.4 108.1%  
P/CF ratio (eoy) x14.215.0 94.6%  
Price / Book Value ratio x2.43.0 79.2%  
Dividend payout %21.520.5 104.9%   
Avg Mkt Cap Rs m379,912474,831 80.0%   
No. of employees `00025.821.7 119.4%   
Total wages/salary Rs m30,27033,802 89.6%   
Avg. sales/employee Rs Th6,459.68,091.0 79.8%   
Avg. wages/employee Rs Th1,171.21,561.3 75.0%   
Avg. net profit/employee Rs Th580.2935.8 62.0%   
INCOME DATA
Net Sales Rs m166,949175,170 95.3%  
Other income Rs m3,4426,206 55.5%   
Total revenues Rs m170,391181,376 93.9%   
Gross profit Rs m32,06024,421 131.3%  
Depreciation Rs m11,74711,348 103.5%   
Interest Rs m1,974983 200.8%   
Profit before tax Rs m21,78218,296 119.1%   
Minority Interest Rs m-4750-   
Prior Period Items Rs m0561 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6,312-1,403 -449.9%   
Profit after tax Rs m14,99520,260 74.0%  
Gross profit margin %19.213.9 137.7%  
Effective tax rate %29.0-7.7 -377.9%   
Net profit margin %9.011.6 77.7%  
BALANCE SHEET DATA
Current assets Rs m117,038125,991 92.9%   
Current liabilities Rs m43,93172,141 60.9%   
Net working cap to sales %43.830.7 142.4%  
Current ratio x2.71.7 152.5%  
Inventory Days Days9673 131.0%  
Debtors Days Days85105 81.2%  
Net fixed assets Rs m107,42483,854 128.1%   
Share capital Rs m1,613831 194.0%   
"Free" reserves Rs m156,018155,157 100.6%   
Net worth Rs m157,630155,988 101.1%   
Long term debt Rs m23,6931,304 1,816.9%   
Total assets Rs m236,626232,253 101.9%  
Interest coverage x12.019.6 61.4%   
Debt to equity ratio x0.20 1,798.0%  
Sales to assets ratio x0.70.8 93.5%   
Return on assets %7.29.1 78.4%  
Return on equity %9.513.0 73.2%  
Return on capital %12.812.6 101.8%  
Exports to sales %33.00-   
Imports to sales %00-   
Exports (fob) Rs m55,175NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,03684,193 66.6%   
Fx outflow Rs m6,76439,616 17.1%   
Net fx Rs m49,27244,577 110.5%   
CASH FLOW
From Operations Rs m30,68529,841 102.8%  
From Investments Rs m1,040-4,923 -21.1%  
From Financial Activity Rs m-29,488-25,159 117.2%  
Net Cashflow Rs m2,340-266 -879.8%  

Share Holding

Indian Promoters % 16.0 25.5 62.7%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 5.4 225.9%  
FIIs % 23.7 35.3 67.1%  
ADR/GDR % 1.1 18.5 5.9%  
Free float % 26.2 15.3 171.2%  
Shareholders   161,166 75,885 212.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   ALEMBIC  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  FDC  SUN PHARMA  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Recover From Day's Low to End Strong; JSW Steel and ICICI Bank Among Top Nifty Gainers(Closing)

Indian share markets recouped early losses during afternoon deals and ended today's volatile session higher.

Related Views on News

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Apr 22, 2021 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS